

Principal Pharmaceuticals & Chemicals Ltd.
513, Palm Spring, Link Road, Malad West, Mumbai - 400 064
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH Sept, 2010

Rs. In lacs except EPS

Sr. No.		3 Months ended	3 Months ended	6 Months ended on	6 Months ended on	Audited
		30th Sept, 2010	30th Sept., 2009	30th Sept, 2010	30th Sept, 2009	Year ended 31st March, 2010
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	
1	Net Sales/Income from Operations	4.50	3.00	9.00	9.49	17.21
2	Other Income	-	0.02	-	0.03	0.11
	Total Income	4.50	3.02	9.00	9.52	17.32
3	Total Expenditure					
a.	(Increase)/decrease in stock trade	-	-	-	-	-
b.	Consumption of raw materials / Purchases	-	-	-	0.09	0.31
c.	Staff Cost	0.38	-	0.75	0.73	1.53
d.	Power & Fuel & Oil	-	-	-	-	-
e.	Job processing charges	-	-	-	-	-
f.	Internet Business Development Cost	-	-	-	-	-
g.	Other expenditure	0.21	0.54	1.14	2.65	13.38
4	Interest	-	-	-	-	-
5	Depreciation & Amortisation	9.23	9.23	18.47	18.44	36.93
6	Profit/(Loss) before tax (1+2-3-4-5)	(5.32)	(6.75)	(11.36)	(12.39)	(34.83)
	Less :					
7	Interest for earlier years	-	-	-	-	-
8	Provision for taxation					
	- Current Year Tax	-	-	-	-	-
	- Deferred Tax	-	-	-	-	-
	- Fringe Benefit Tax	-	-	-	-	-
9	Net Profit / (Loss) (6-7)	(5.32)	(6.75)	(11.36)	(12.39)	(34.83)
	Extraordinary Items					
10	Add : Credits due to restructured liabilities	-	-	-	-	-
11	Balance carried to the balance sheet	(5.32)	(6.75)	(11.36)	(12.39)	(34.83)
12	Paid-up equity share capital (Face value Rs 10/- each)	599.97	599.97	599.97	599.97	599.97
13	Reserve excluding revaluation reserves (Net of debit balance of Profit & Loss Account)					(664.59)
14	Basic & diluted EPS for the period, for the year to date & for the previous year (prior to extra ordinary item) (not to be annualised)	(0.09)	(0.11)	(0.19)	(0.21)	(0.58)
15	Basic & diluted EPS for the period, for the year to date & for the previous year (after extra ordinary item) (not to be annualised)	(0.09)	(0.11)	(0.19)	(0.21)	(0.58)
16	Aggregate of Non-Promoters' Shareholding					
	No. of shares (in lacs)	40.79	40.79	40.79	40.79	40.79
	Percentage of Shareholding	67.99%	67.99%	67.99%	67.99%	67.99%
17	Promoters and Promoter Group Shareholding					
a.	Pledged /Encumbered					
	- No. of Shares (in lacs)	-	14.14	-	14.14	-
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	-	73.65%	-	73.65%	-
	- Percentage of Shares (as a % of total sharecapital of the company)	-	23.57%	-	23.57%	-
b.	Non - Encumbered					
	- No. of Shares (in lacs)	19.21	5.07	19.21	5.07	19.21
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	100.00%	26.35%	100.00%	26.35%	100.00%
	- Percentage of Shares (as a % of total sharecapital of the company)	32.01%	8.43%	32.01%	8.43%	32.01%

1 No separate segment results are provided as the total revenue of the Company is from i.e. Active Pharmaceuticals Intgredients (API) & Intermediates. There is no revenue during the Quarter from eCommerce and Software services activities.

2 The Company was declared as "Sick Company" by the Board for Industrial & Financial Reconstruction u/s 3(1)(o) of Sick Industrial Companies (Special Provision) Act, 1985. An order to that effect was received by the company in October, 2005. According to the latest directives BIFR, the Company prepared and submitted rehabilitation scheme to the operating agency which is under consideration before the H'ble Board. The company has settled & paid all its dues to all its secured creditors.

3 BSE has not yet revoked the suspension order though the company has complied with all the provisions of the listing agreement and paid listing fee upto March, 2011.

4 There were no complaints pending at the beginning of 2nd Quarter . Complaints received during 2nd Quarter - NIL; Complaints solved during 2nd Quarter - NIL; Complaints pending at the end of 2nd Quarter - NIL.

5 The above results have been reviewed and taken on record at the meeting of the Audit Committee and the Board of Directors held on 30th October, 2010.

By Order of the Board

Place : Mumbai
Dated : 30th October, 2010

Pradeep Malu
President & CEO